AusBioInvest 2023 programme launched


Australia’s premier life science investment conference unveils esteemed speaker lineup and 26 Australian biotech companies pitching for partnerships.

The programme for AusBioInvest 2023 is now live, featuring an industry-led programme with thought-provoking keynote and panel sessions with leading investors and business leaders.

The programme includes a fireside chat with Jennifer Nason, Global Chairman, Investment Banking, J.P. Morgan, who will provide an update on global capital market trends, conditions and themes and what it means for Australian biotechs; Kanishka Pothula, Partner, Nextech, will participate in a fireside on considerations US investors make when evaluating a deal, with a focus on non-specialist investors navigating the sector; while Ajita Tynan, Manager, Listed Company Services, Australian Securities Exchange, will provide an update on the public markets in Australia.

In addition, AusBioInvest 2023 features a presentation from 26 Australian biotech companies, spanning early- to late-stage, actively seeking investors or partners to support their funding and co-development.

Presenting companies include Arovella Therapeutics (ASX:ALA), Avecho Biotechnology (ASX:AVE), BiomeBank, Carina Biotech, Celosia Therapeutics, Cyban, Dimerix (ASX:DXB), EBR Systems (ASX:EBR), Encapsolutions, ESFAM Biotech, FivepHusion, Genofax, Imagion Biosystems (ASX:IBX), Immuron Limited (ASX:IMC), InhaleRx (ASX:IRX), Invion (ASX: IVX), LBT Innovations (ASX:LBT), Microba, Noxopharm Limited (ASX:NOX), PolyActiva, Prescient Therapeutics (ASX:PTX), Respiri (ASX:RSH), Snoretox, TruScreen (ASX:TRU), Tessara Therapeutics, and Vaxxas.

AusBiotech CEO Lorraine Chiroiu said, “Access to capital remains one of the biggest barriers for biotech companies in Australia. AusBioInvest fosters meaningful connections between the investment community and investment-seeking life sciences companies, enabling great ideas to attract risk-tolerant capital while assisting investors to connect with innovative, Australian companies that offer high-value return-on-investment.”

Stepping onto the stage of AusBioInvest 2023, delegates can hear the latest insights and trends in life science investing from global and local experts and make meaningful connections with leading local biotech executives from publicly listed and privately owned companies as they pitch their breakthrough health innovations to investors.

Held at the Park Hyatt in Melbourne, AusBioInvest’s registered delegates represent Australia’s leading life science companies, and Australian and global investors represent venture capital firms, private equity firms, high net worth individuals, research analysts and brokers, industry executives and major global stakeholders.

Qualified investors are invited to register for their complimentary pass today and to hear from their peers as well as the latest from Australian innovators. Delegates that do not fit within the Qualified Investor criteria are invited to register as an AusBioInvest 2023 delegate.

Thank you to AusBiotech’s Investment Advisory Group for their support in developing the programme.

Register for AusBioInvest 2023 here.